Pfizer and BioNTech achieve Health Canada authorization for their vaccine to com
Pfizer Canada and BioNTech announced that Health Canada has granted Authorization under Interim Order for the emergency use of their mRNA COVID-19 vaccine (BNT162b2). The distribution of the vaccine in Canada will be prioritized according to the populations identified in guidance from the National Advisory Committee on Immunizations (NACI). BioNTech will hold the regulatory approval in Canada, while Pfizer Canada will have the commercialization rights.
Pfizer Canada and BioNTech will supply the Government of Canada a minimum of 20 million doses (and up to 76 million doses) of the vaccine through 2021.
2026-09-20
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Which Companies Are Making Covid Vaccines
-
The Indian Variant Vaccine Efficacy is only 10%, and it was abandoned by South Africa
-
Compensation Methods For Adverse Reactions To Vaccines In The Post-Epidemic Period
-
The Johnson & Johnson Vaccine Is Only 72% Effective, Is It An Inferior Vaccine?
-
Research On The Distribution Of The Incubation Period Of COVID-19
-
How Many Covid Vaccines Are Made Per Second?
-
Protein Based Vaccines Examples : The Second Generation Of The COVID-19 Vaccine Is Coming
-
Does Vaccine Protect Against Omicron? Zhang Wenhong : Vaccination Booster Is Still An Effective Tool To Deal With Omicron
-
Are Covid Vaccines Patented ?
-
Several Domestic New Crown Mrna Companies Turn To Developing Broad-Spectrum Vaccines, Exploring Against Different Mutant Strains
Recommend Reading
-
Henkel's Acquisition of Stahl Enters Regulatory Countdown: Will the €2.1 Billion Deal Go Through?
-
Sinopec Builds 146 Hydrogen Refueling Stations, Ranking Among the World’s Largest Operators
-
Givaudan Breaks Ground on New Fragrance Factory in Guangzhou
-
Argentina to Build Latin America’s Largest Urea Plant Under €1.3 Billion Contract
-
Dow Swings from an $801 Million Loss to an $802 Million Profit as Hormuz Disruption Lifts Polyethylene Prices
-
March DOP Market in China Experiences Sharp Fluctuations and Rises
-
Maintenance Peak & Raw Material Prices Soaring—PP Rises Another 7% in a Single Day
-
Cost Values Fluctuating, PC Market Prices Volatile at High Levels
-
Supply and Demand Weakness, Flexible Fluctuations in the Melamine Market
-
Rate of Change Turns Negative—Retail Prices for Refined Oil Products to Be Lowered This Round